581 related articles for article (PubMed ID: 3097872)
1. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
Gurewich V; Pannell R
Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
[TBL] [Abstract][Full Text] [Related]
2. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
Liu JN; Gurewich V
J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471
[TBL] [Abstract][Full Text] [Related]
4. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
Lijnen HR; Dewerchin M; De Cock F; Collen D
Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
[TBL] [Abstract][Full Text] [Related]
5. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.
Pannell R; Gurewich V
Blood; 1986 May; 67(5):1215-23. PubMed ID: 3083889
[TBL] [Abstract][Full Text] [Related]
6. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis.
Loza JP; Gurewich V; Johnstone M; Pannell R
Thromb Haemost; 1994 Mar; 71(3):347-52. PubMed ID: 8029800
[TBL] [Abstract][Full Text] [Related]
7. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
Gurewich V; Pannell R; Broeze RJ; Mao J
J Clin Invest; 1988 Dec; 82(6):1956-62. PubMed ID: 2974047
[TBL] [Abstract][Full Text] [Related]
9. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
11. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
Watahiki Y; Scully MF; Ellis V; Kakkar VV
Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
[TBL] [Abstract][Full Text] [Related]
12. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
Gurewich V; Pannell R
Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
[No Abstract] [Full Text] [Related]
13. Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro.
Martin U; Sponer G; Strein K
Blood Coagul Fibrinolysis; 1993 Apr; 4(2):235-42. PubMed ID: 8388740
[TBL] [Abstract][Full Text] [Related]
14. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
Lijnen HR; De Wreede K; Demarsin E; Collen D
Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
[TBL] [Abstract][Full Text] [Related]
15. Activation of fibrin-bound plasminogen by pro-urokinase and its complementariness with that by tissue plasminogen activator.
Gurewich V
Enzyme; 1988; 40(2-3):97-108. PubMed ID: 2971533
[TBL] [Abstract][Full Text] [Related]
16. Comparison of affinities of urokinase and tissue plasminogen activator for fibrin clots.
Homandberg GA; Wai T
Thromb Res; 1989 Aug; 55(4):493-501. PubMed ID: 2510355
[TBL] [Abstract][Full Text] [Related]
17. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
[TBL] [Abstract][Full Text] [Related]
18. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
Dewerchin M; Lijnen HR; Stassen JM; De Cock F; Quertermous T; Ginsberg MH; Plow EF; Collen D
Blood; 1991 Aug; 78(4):1005-18. PubMed ID: 1831057
[TBL] [Abstract][Full Text] [Related]
19. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.
Gurewich V; Pannell R; Louie S; Kelley P; Suddith RL; Greenlee R
J Clin Invest; 1984 Jun; 73(6):1731-9. PubMed ID: 6725557
[TBL] [Abstract][Full Text] [Related]
20. Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.
Samama M; Nguyen G; Desnoyers P; Lourenco DM; Fretault J; Horellou MH; Conard J; Szwarcer E; Verdy E; Vahanian A
Fundam Clin Pharmacol; 1988; 2(6):509-23. PubMed ID: 3149257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
